ABSTRACT
Coronary artery disease (CAD) is highly heritable and remains the leading cause of mortality worldwide. Understanding the genetic and mechanistic underpinnings of CAD is crucial for early risk assessment and intervention. We conducted a transcriptome-wide Mendelian randomisation (MR) study, utilising unbiased tissue-specific gene regulatory networks, to identify genes causally associated with CAD in European and East Asian populations. We identified 291 tissue and ancestry-specific genes implicated in CAD, including 98 novel protein-coding genes across coronary artery, whole blood, and lung tissues. Genes involved in epigenetic processes (eg PAXBP and KIAA0232) causally associated with CAD. Moreover, we identified genes related to the ubiquitin-proteasome system in the coronary artery and kinase signalling in the lung, as being causally related to CAD. The integration of protein interaction networks identified causal connections between CAD and HDL cholesterol levels, providing novel insights into CAD mechanisms, and potential actionable targets for people with this risk profile. The results also provide intriguing insights into the link between SARS-CoV-2 and CAD, unveiling mechanisms that may underlie the increased risk of cardiovascular disease following SARS-CoV-2 infection. The causal mechanisms we identified emphasise the tissue-agnostic and ancestrally unique pathways that underscore the complex interplay between CAD development, metabolic disturbances, and the immune system. Collectively, our results provide valuable insights into CAD pathogenesis and potential therapeutic targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Sir Colin Giltrap Liggins Institute Scholarship funded RKJ. The Dines Family Charitable Trust funds JOS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only openly available human data that were orginally located at:European GWAS Data for CAD: https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST005195/ East Asian GWAS Data for CAD: https://gwas.mrcieu.ac.uk/datasets/bbj-a-159
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are avialble at: European GWAS Data for CAD: https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST005195/ East Asian GWAS Data for CAD: https://gwas.mrcieu.ac.uk/datasets/bbj-a-159 Two-Sample MR package: https://mrcieu.github.io/TwoSampleMR/
https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST005195/
